Sen. Bernie Sanders renewed criticism of Novo Nordisk, claiming that generic drugmakers could produce and sell Ozempic for under $100 a month, much less than the current $1,300 U.S. price tag. Sanders made this remark at a Capitol Hill roundtable ahead of Novo Nordisk CEO Lars Fruergaard Jørgensen’s Senate testimony on the drug’s pricing.

Ozempic has gained popularity nationwide for its proven benefits in achieving weightloss.

Sanders has led an investigation into Novo Nordisk’s pricing, pointing out that Ozempic is significantly cheaper in countries like Denmark and the U.K. He condemned the high U.S. prices as “corporate greed,” noting that the actual cost of producing the drug is much lower. However, due to patent protections, generic manufacturers cannot sell a lower-priced version.

Novo Nordisk responded by stating that the net price of Ozempic has decreased 40% since its U.S. approval in 2017, with a similar trend for its weight-loss drug, Wegovy.